Skip to content

A clinical evaluation of Nityavirechanakarma (By Aragwadh Phalamajja) treated with Navkarshikaguggulu in the management of Sheetapitta (urticaria)

A clinical evaluation of Nityavirechanakarma (By Aragwadh Phalamajja) treated with Navkarshikaguggulu in the management of Sheetapitta (urticaria) An open labeled randomized comparative clinical trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/055953
Enrollment
30
Registered
2023-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L503- Dermatographic urticaria

Interventions

None listed

Sponsors

Government Akhandanand Ayurveda college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient having minimum two classical signs and symptoms of Sheetapitta like varatidashtasansthan vat shoth, Kandu

Exclusion criteria

Exclusion criteria: Patient having age less then 18years and more than 60years will be excluded. Disease like, Angio edema, Diabetes mellitus, T.B.infection, Myocardial infarction, Congestive cardiac failure, various kind of Leprosy, AIDS and other systemic disorders that may lead fatal condition will be excluded.

Design outcomes

Primary

MeasureTime frame
The efficacy of treatment will be assessed on the basis of the diagnostic criteria. varatidashtasansthanvat shoth,kandu,toda,chardi,vidahTimepoint: Follow up will be taken after the completion of treatment for every week up to 2 weeks

Secondary

MeasureTime frame
Patient will be assessed on the basis of Vartidashtasansthanvatshoth,kandu,toda,chardi,jwara,vidahaTimepoint: follow uo will bw taken after the completion of treatment for every week up to 2 weeks

Countries

India

Contacts

Public ContactVd Hemang U Raghwani

Government Akhandanand Ayurveda college

vdhemang@gmail.com9925008060

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026